Is forteo safe?

Is Forteo safe for long-term use?

Forteo (teriparatide) is approved for up to two years of continuous treatment. Clinical studies show that longer use raises the theoretical risk of osteosarcoma seen in rat studies, so the FDA caps therapy at 24 months. Once the limit is reached, patients switch to other agents such as bisphosphonates or denosumab to maintain bone density.

What side effects do patients report most often?

The most common complaints are transient dizziness, leg cramps, and injection-site reactions. Nausea and joint pain occur less frequently. Most symptoms lessen after the first few doses and rarely require stopping therapy.

Can you restart Forteo after finishing the two-year course?

Current labeling does not support retreatment. The safety of a second course has not been established, and cumulative lifetime exposure beyond two years has not been studied in humans.

How does Forteo compare with Prolia or bisphosphonates?

Forteo increases bone formation directly, producing larger gains in spine bone density than anti-resorptive drugs. Prolia and bisphosphonates primarily slow bone loss and carry different risks such as atypical femur fractures or osteonecrosis of the jaw. Choice depends on fracture risk, prior treatment history, and patient tolerance.

When does the Forteo patent expire?

The composition-of-matter patent for teriparatide expired in 2019, but remaining device and formulation patents extend protection. A generic teriparatide pen is now available in some markets, which has reduced cost for eligible patients.

Who makes Forteo and what does treatment cost?

Eli Lilly manufactures the brand product. Without insurance, list price exceeds $3,500 per month. Medicare Part D and many commercial plans cover the drug after prior authorization, and patient-assistance programs can lower out-of-pocket expense.

[1] https://www.drugpatentwatch.com/drug/forteo